ArticleQuantitative imaging in medicine and surgery2019
Photoacoustic imaging for the evaluation of early tumor response to antivascular treatment.
Article in Quantitative imaging in medicine and surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Harnessing Rare-Earth Materials as Exogenous Contrast Agents for Enhanced Photoacoustic Imaging.Chemical & biomedical imaging · 2026Review
- Listening to Immunotherapy - Ultrasound and Photoacoustic Imaging Strategies to Guide and Enhance Cancer Treatments.Molecular imaging and biology · 2026Review
- Quantitative longitudinal photoacoustic imaging of vascular oxygenation for therapy response monitoring in Non-Hodgkin lymphoma.Photoacoustics · 2026Article
- Assessing axitinib-induced differential responses in tumor vascularization and oxygenation with combined optoacoustic angiography and diffuse optical spectroscopy.Neoplasia (New York, N.Y.) · 2026Article
- Multivalent fusion protein targeting VEGFR2 and DR5 receptors: assessing the antiangiogenic and antitumor effects via multimodal microangiography.Journal of translational medicine · 2025Article
- Heterogeneous tumor blood oxygenation dynamics during phototherapy deciphered with real-time label-free photoacoustic imaging.NPJ acoustics · 2025Article
- In vivo, online label-free monitoring of heterogenous oxygen utilization during phototherapy with real-time ultrasound-guided photoacoustic imaging.bioRxiv : the preprint server for biology · 2024Article
- Review on Photoacoustic Monitoring after Drug Delivery: From Label-Free Biomarkers to Pharmacokinetics Agents.Pharmaceutics · 2024Review
- Review of imaging test phantoms.Journal of biomedical optics · 2023Review
- Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.Signal transduction and targeted therapy · 2023Review
- Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.Cancer research · 2022Article
- Progress of photoacoustic imaging combined with targeted photoacoustic contrast agents in tumor molecular imaging.Frontiers in chemistry · 2022Review
- Photoacoustic microscopy: a novel approach for studying perforator skin flap in a mouse model.Quantitative imaging in medicine and surgery · 2021Article
- Vascular normalisation as the stepping stone into tumour microenvironment transformation.British journal of cancer · 2021Review
- Expanded porphyrins: functional photoacoustic imaging agents that operate in the NIR-II region.Chemical science · 2021Article
- Photoacoustic imaging as a highly efficient and precise imaging strategy for the evaluation of brain diseases.Quantitative imaging in medicine and surgery · 2021Review
- Photoacoustic monitoring of oxygenation changes induced by therapeutic ultrasound in murine hepatocellular carcinoma.Scientific reports · 2021Article
- Oxygen-Enhanced Optoacoustic Tomography Reveals the Effectiveness of Targeting Heme and Oxidative Phosphorylation at Normalizing Tumor Vascular Oxygenation.Cancer research · 2020Article
- Photoacoustic image-guided interventions.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Development of a blood oxygenation phantom for photoacoustic tomography combined with online pO2 detection and flow spectrometry.Journal of biomedical optics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhotoacoustic imaging (PAI) provides real-time noninvasive and contrast agent-free monitoring of the concentrations of some endogenous compounds related to tumor vascularization and oxygenation. In this study, we used PAI to noninvasively evaluate tumor responses to antiangiogenic therapy.
methodsIn vivo studies were performed with the approval of our institutional animal ethics committee. We used a xenograft mouse model of 4T1 breast cancer treated with different doses of bevacizumab or vehicle. Seven days after implantation, tumor-bearing mice (with tumors ~5-8 mm diameter) were randomly divided into low-dose (10 mg/kg), high-dose (20 mg/kg) and vehicle groups (same dose of saline). Each experimental group was administered bevacizumab intraperitoneally only once. Before and after treatment, acoustic resolution-photoacoustic microscopy (AR-PAM), a type of PAI, was conducted
resultsThe values of the PAI parameters were not significantly different among the experimental and control groups at the same time point before treatment (all P>0.05). The total hemoglobin (HbT) levels in the treatment group gradually decreased from day 1 to day 2 (relative to those in the control group, P>0.05) and decreased significantly relative to those in the control group from day 3 to day 5 (P<0.05). The deoxyhemoglobin (HbR) levels in the treatment group decreased from day 1 to 5 after treatment. The high-dose group had significantly decreased HbR levels relative to the control group from day 1 to 5 (P<0.05). The low-dose group also showed a gradual and significant decrease in HbR levels on day 3 (P<0.05). CD31 was decreased in the low-dose group relative to the control group on day 1 (decreased by 34.05%, P=0.067) and day 3 (decreased by 45.27%, P=0.180), and the decrease in CD31 persisted on day 5 (decreased by 71.41%, P=0.000). CD31 decreased to a greater extent in the high-dose group than in the low-dose group. Tumor hypoxia was significantly increased on day 1 from day 0 in the treatment groups (P<0.05), especially in the high-dose group. Hypoxia was decreased on days 3 and 5 in the low-dose group (10.92±0.92 and 8.17±1.9, P=0.317) but continuously increased over time in the high-dose group. Significantly greater hypoxia was observed in the high-dose group than in the low-dose group (17.60±1.20 and 20.33±0.47, P<0.05).
conclusionsPAI can be used to evaluate both vessel regression and hypoxia in response to anti-vascular treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.